We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Adolor’s Intestinal Drug Misses on Two of Three Trials
Adolor’s Intestinal Drug Misses on Two of Three Trials
September 5, 2006
Adolor’s stock took a major hit after the company and GlaxoSmithKline announced data showing that their new drug alvimopan, designed to treat opioid-induced bowel dysfunction (OBD), was ineffective in two of three clinical trials.